Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

About this update from Eton Pharmaceuticals, Inc.

DEER PARK, Ill. , May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025 . Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET ( 3:30 p.m. CT ). Dial In* (Audio Only) Click Here Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: [email protected] .The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/ . An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter. *Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET- 400, ET -600, Amglidia®, ET- 700, ET -800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com . Investor Relations: Lisa M. Wilson In-Site Communications, Inc. T: 212-452-2793E: [email protected] Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

View stock analysis, news, and events for Eton Pharmaceuticals, Inc.